Alnylam Pharmaceuticals, Inc. is rated Hold due to high expectations, competitive threats, and revenue expansion. Learn more about ALNY stock here.

FTC fast-tracks antitrust approval of earlier deal in sign Washington could weigh in on takeover battle with Novo Nordisk ...

While Pfizer called the bid “reckless”, Metsera disagrees, stating that it will review the “superior proposal”.

That is a sizeable increase on Pfizer's September offer of $47.50 upfront and $22.50 in CVRs, which combined to give a deal ...

Pfizer says Novo Nordisk bid breaks law, calling the $9B Metsera offer an illegal attempt to eliminate a U.S. competitor with antitrust risks.

Pfizer (PFE) shares have been inching upward recently, sparking some fresh attention from investors looking to understand ...

Danish pharmaceutical giant Novo Nordisk, maker of weight-loss drugs Ozempic and Wegovy, announced Thursday an unsolicited bid to acquire obesity treatment maker Metsera, topping an offer from US ...

Danish drugmaker Novo Nordisk A/S offered to acquire obesity startup Metsera Inc. for at least $6.5 billion, seeking to trump ...

Pfizer Inc. has four days. Danish drugmaker Novo Nordisk A/S upended the US pharma giant’s deal to acquire obesity upstart ...

Danish pharmaceutical giant Novo Nordisk, maker of weight-loss drugs Ozempic and Wegovy, has announced an unsolicited bid to ...

Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $20.0 to $30.0 for Pfizer during the past quarter. Looking at the volume ...

In the rapidly evolving landscape of global pharmaceuticals, China has emerged as a formidable player, transitioning from a dominant producer of generic drugs to a hub for innovative medicines. Over ...